| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.4155/TDE.15.30 |
| P698 | PubMed publication ID | 26228775 |
| P2093 | author name string | Gene L Bidwell | |
| Jeremy Wd McGowan | |||
| Parminder Js Vig | |||
| P2860 | cites work | The blood-brain barrier: bottleneck in brain drug development | Q22336985 |
| Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brain | Q27331875 | ||
| Therapeutic nanoparticles for drug delivery in cancer | Q28271255 | ||
| A new brain drug delivery strategy: focused ultrasound-enhanced intranasal drug delivery | Q28543529 | ||
| In vivo protein transduction: delivery of a biologically active protein into the mouse | Q29615482 | ||
| The size of blood-brain barrier opening induced by focused ultrasound is dictated by the acoustic pressure | Q30407897 | ||
| Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy | Q44091331 | ||
| The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. | Q44360602 | ||
| Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits | Q44590646 | ||
| Toxicity and tissue distribution of magnetic nanoparticles in mice. | Q46764075 | ||
| Mannitol enhances therapeutic effects of intra-arterial transplantation of mesenchymal stem cells into the brain after traumatic brain injury | Q46802118 | ||
| Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas | Q46825473 | ||
| Effects of nanoparticles on the adhesion and cell viability on astrocytes. | Q46965962 | ||
| Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides | Q48099988 | ||
| The improved blood-brain barrier permeability of endomorphin-1 using the cell-penetrating peptide synB3 with three different linkages | Q48524934 | ||
| Enhancement of brain distribution of anticancer agents using DeltaG, the 12 kDa active fragment of ZOT. | Q48704302 | ||
| Determination of tissue levels of a neuroprotectant drug: the cell permeable JNK inhibitor peptide | Q48782705 | ||
| Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier | Q48822708 | ||
| Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. | Q50527409 | ||
| Tracking the in vivo fate of recombinant polypeptides by isotopic labeling. | Q50745066 | ||
| The factors that influence permeation across the blood-brain barrier. | Q52410552 | ||
| Drug transport across the blood-brain barrier | Q57677287 | ||
| Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model | Q30458838 | ||
| The design and delivery of a thermally responsive peptide to inhibit S100B-mediated neurodegeneration | Q30460371 | ||
| Drug-like properties and the causes of poor solubility and poor permeability | Q30660926 | ||
| Identification and expression profiling of blood-brain barrier membrane proteins | Q33515413 | ||
| Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy | Q33569245 | ||
| Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy | Q33770621 | ||
| The transferrin receptor: role in health and disease | Q33785145 | ||
| The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells. | Q34018635 | ||
| Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro | Q34058314 | ||
| Intranasal administration as a route for drug delivery to the brain: evidence for a unique pathway for albumin | Q34186253 | ||
| Fusion of cell-penetrating peptides to thermally responsive biopolymer improves tumor accumulation of p21 peptide in a mouse model of pancreatic cancer | Q34353772 | ||
| Design and screening of a glial cell-specific, cell penetrating peptide for therapeutic applications in multiple sclerosis. | Q34438165 | ||
| Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption | Q34714906 | ||
| A novel platform for engineering blood-brain barrier-crossing bispecific biologics | Q35214538 | ||
| Highly site-selective transvascular drug delivery by the use of nanosecond pulsed laser-induced photomechanical waves | Q35221185 | ||
| Ratiometric activatable cell-penetrating peptides label pancreatic cancer, enabling fluorescence-guided surgery, which reduces metastases and recurrence in orthotopic mouse models | Q35335567 | ||
| Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein | Q36296365 | ||
| IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys | Q36546138 | ||
| Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice | Q36736227 | ||
| Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades. | Q37564522 | ||
| Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor | Q37573901 | ||
| Intranasal delivery to the central nervous system: mechanisms and experimental considerations | Q37624592 | ||
| Devices for overcoming biological barriers: the use of physical forces to disrupt the barriers | Q38041928 | ||
| Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review | Q38200847 | ||
| Subcutaneous drug delivery and the role of the lymphatics | Q38225038 | ||
| Delivery of therapeutic peptides and proteins to the CNS. | Q38259307 | ||
| Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood-Brain Barrier | Q38269392 | ||
| Light induced cytosolic drug delivery from liposomes with gold nanoparticles. | Q38907554 | ||
| ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice | Q38930266 | ||
| Magnetic field enhanced convective diffusion of iron oxide nanoparticles in an osmotically disrupted cell culture model of the blood-brain barrier | Q38975707 | ||
| A thermally targeted peptide inhibitor of symmetrical dimethylation inhibits cancer-cell proliferation. | Q39737800 | ||
| An injectable and in situ-gelling biopolymer for sustained drug release following perineural administration | Q41791113 | ||
| A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension | Q41882126 | ||
| Structural requirements for cellular uptake and antisense activity of peptide nucleic acids conjugated with various peptides | Q41944024 | ||
| Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase A. | Q42235059 | ||
| Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. | Q42273109 | ||
| The design and delivery of a PKA inhibitory polypeptide to treat SCA1. | Q43523795 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 841-853 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | Therapeutic delivery | Q26842827 |
| P1476 | title | Challenges and new strategies for therapeutic peptide delivery to the CNS. | |
| P478 | volume | 6 |
| Q40148221 | Asn194Lys mutation in RVG29 peptide increases GFP transgene delivery by endocytosis to neuroblastoma and astrocyte cells |
| Q92349932 | Established and Emerging Strategies for Drug Delivery Across the Blood-Brain Barrier in Brain Cancer |
| Q33580885 | Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS. |
| Q39483024 | Structural Elucidation of the Cell-Penetrating Penetratin Peptide in Model Membranes at the Atomic Level: Probing Hydrophobic Interactions in the Blood-Brain Barrier |
Search more.